SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination - Summary - MDSpire

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

  • By

  • José Luis Piñana

  • Rodrigo Martino

  • Lourdes Vazquez

  • Lucia López-Corral

  • Ariadna Pérez

  • Pedro Chorão

  • Alejandro Avendaño-Pita

  • María-Jesús Pascual

  • Andrés Sánchez-Salinas

  • Gabriela Sanz-Linares

  • María T. Olave

  • Ignacio Arroyo

  • Mar Tormo

  • Lucia Villalon

  • Venancio Conesa-Garcia

  • Beatriz Gago

  • María-José Terol

  • Marta Villalba

  • Valentín Garcia-Gutierrez

  • Almudena Cabero

  • José Ángel Hernández-Rivas

  • Elena Ferrer

  • Irene García-Cadenas

  • Anabel Teruel

  • David Navarro

  • Ángel Cedillo

  • Anna Sureda

  • Carlos Solano

  • February 28, 2023

  • 0 min

Share

Objective:

To analyze the kinetics of SARS-CoV-2-S-RA and characterize breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients one year after vaccination, focusing on the duration and levels of antibody response.

Key Findings:
  • SARS-CoV-2-S-RA titers wane over time in immunocompromised patients, increasing the risk of severe outcomes.
  • Booster doses can induce higher SARS-CoV-2-S-RA titers, potentially enhancing protection.
  • Breakthrough infections were documented, with varying incidence and severity, underscoring the need for continued vigilance.
Interpretation:

The study highlights the need for ongoing monitoring of antibody responses and the potential benefits of booster vaccinations in immunocompromised populations to mitigate the risk of COVID-19, informing public health strategies.

Limitations:
  • Limited data on the long-term effects of booster doses, which may affect the generalizability of findings.
  • Potential biases in patient selection and follow-up could influence the reliability of the results.
Conclusion:

Continued vaccination efforts, including booster doses, are critical for improving immunity in hematopoietic stem cell transplant and cell therapy recipients, emphasizing the importance of tailored vaccination strategies.

Original Source(s)

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

  • by José Luis Piñana, Rodrigo Martino, Lourdes Vazquez, Lucia López-Corral, Ariadna Pérez, Pedro Chorão, Alejandro Avendaño-Pita, María-Jesús Pascual, Andrés Sánchez-Salinas, Gabriela Sanz-Linares, María T. Olave, Ignacio Arroyo, Mar Tormo, Lucia Villalon, Venancio Conesa-Garcia, Beatriz Gago, María-José Terol, Marta Villalba, Valentín Garcia-Gutierrez, Almudena Cabero, José Ángel Hernández-Rivas, Elena Ferrer, Irene García-Cadenas, Anabel Teruel, David Navarro, Ángel Cedillo, Anna Sureda, Carlos Solano

  • February 28, 2023

Related Content

Pediatric Acute Respiratory Virus Hospitalizations: A Population-Based Cohort Study, 2017–2024

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19